Y-mAbs Therapeutics Q2 Revenue Falls 14% Amid Acquisition Talks

Y-mAbs Therapeutics reported a 14% fall in Q2 revenue, while SERB Pharmaceuticals agreed to acquire the company for approximately $390 million. Several brokerages downgraded Y-mAbs Therapeutics, including Morgan Stanley, Cantor Fitzgerald, Oppenheimer, and Wedbush.

Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) reported a 14.3% year-over-year (YoY) decline in revenue for the second quarter (Q2) of 2025, with total revenue of $19.53 million. This figure was $1.13 million less than the consensus estimate of $20.66 million. The company's GAAP earnings per share (EPS) for the quarter were -$0.07, beating the estimated -$0.19 [1].

Despite the revenue decline, Y-mAbs Therapeutics has been acquired by SERB Pharmaceuticals in a deal valued at approximately $390 million. The acquisition includes the transfer of Danyelza (naxitamab-gqgk), an FDA-approved therapy for neuroblastoma, to SERB Pharmaceuticals [2]. This move is part of SERB's strategy to expand its presence in rare and pediatric oncology.

Several brokerages have recently downgraded Y-mAbs Therapeutics. Morgan Stanley, Cantor Fitzgerald, Oppenheimer, and Wedbush have all issued negative ratings on the company's stock, citing concerns about prolonged development timelines and limited near-term catalysts [3].

The acquisition by SERB Pharmaceuticals is expected to provide Y-mAbs Therapeutics with additional financial resources and strategic support to continue its research and development efforts. However, the company will need to navigate the challenges of integrating with a larger organization and maintaining its pipeline of innovative cancer therapies.

References:
1. [1] https://seekingalpha.com/news/4482383-y-mabs-therapeutics-gaap-eps-of-0_07-beats-by-0_19-revenue-of-19_53m-beats-by-1_13m
2. [2] https://www.geneonline.com/serb-pharmaceuticals-acquires-y-mabs-therapeutics-in-412-million-deal-including-neuroblastoma-drug-danyelza/
3. [3] https://www.marketwatch.com/investing/stock/ymab